Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

被引：1
|
作者：
Shah, Jatin J. [1 ]
Feng, Lei [1 ]
Manasanch, Elisabet E. [1 ]
Weber, Donna M. [1 ]
Thomas, Sheeba K. [1 ]
Turturro, Francesco [1 ]
Alexanian, Raymond [1 ]
Shah, Nina [1 ]
Popat, Uday R. [1 ]
Nieto, Yago [1 ]
Bashir, Qaiser [1 ]
Qazilbash, Muzaffar H. [1 ]
Champlin, Richard E. [2 ]
Orlowski, Robert Z. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
    Shah, Jatin J.
    Feng, Lei
    Manasanch, Elisabet E.
    Weber, Donna
    Thomas, Sheeba K.
    Turturro, Francesco
    Shah, Nina
    Popat, Uday R.
    Nieto, Yago
    Bashir, Qaiser
    Munoz, Silvia C.
    Landry, Ashley
    Mendoza, Kathleen
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    Orlowski, Robert Z.
    BLOOD, 2015, 126 (23)
  • [2] The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma
    Okazuka, Kiyoshi
    Ishida, Tadao
    Nashimoto, Junichiro
    Uto, Yui
    Sato, Kota
    Miyazaki, Kanji
    Ogura, Mizuki
    Yoshiki, Yumiko
    Abe, Yu
    Tsukada, Nobuhiro
    Suzuki, Kenshi
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (02) : 110 - 115
  • [3] Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
    Voorhees, Peter M.
    Kaufman, Jonathan L.
    Laubach, Jacob
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca
    Costa, Luciano J.
    Anderson, Larry D., Jr.
    Nathwani, Nitya
    Shah, Nina
    Efebera, Yvonne A.
    Holstein, Sarah A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Murphy, Sean
    Lutska, Yana
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    de Boer, Carla
    Hoehn, Daniela
    Lin, Thomas S.
    Richardson, Paul G.
    BLOOD, 2020, 136 (08) : 936 - 945
  • [4] Efscalefect of lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy in transplant-eligible patients (Pts) with newly diagnosed multiple myeloma (MM) on CR rates and survival.
    Gleason, Charise
    Nooka, Ajay K.
    Muppidi, Samatha
    Heffner, Leonard T.
    Steuer, Conor E.
    Kumar, Mukesh
    Casbourne, Daniela
    Langston, Amelia A.
    Watson, Melanie
    Boise, Lawrence
    Kaufman, Jonathan L.
    Lonial, Sagar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis
    Kazuhito Suzuki
    Nobuhiro Tsukada
    Noriko Nishimura
    Yasuyuki Nagata
    Kiyoshi Okazuka
    Yuko Mishima
    Masahiro Yokoyama
    Kaichi Nishiwaki
    Tadao Ishida
    Shingo Yano
    Yasuhito Terui
    Kenshi Suzuki
    International Journal of Hematology, 2020, 111 : 103 - 111
  • [6] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    Rodriguez, Cesar
    Jakubowiak, Andrzej
    Efebera, Yvonne
    Reeves, Brandi
    Wildes, Tanya
    Holstein, Sarah A.
    Anderson, Larry D., Jr.
    Badros, Ashraf
    Shune, Leyla
    Chari, Ajai
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Bartlett, J. Blake
    Vermeulen, Jessica
    Lin, Thomas S.
    Richardson, Paul G.
    Voorhees, Peter
    BLOOD CANCER JOURNAL, 2022, 12 (04)
  • [7] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
    Ajay K. Nooka
    Jonathan L. Kaufman
    Cesar Rodriguez
    Andrzej Jakubowiak
    Yvonne Efebera
    Brandi Reeves
    Tanya Wildes
    Sarah A. Holstein
    Larry D. Anderson
    Ashraf Badros
    Leyla Shune
    Ajai Chari
    Huiling Pei
    Annelore Cortoos
    Sharmila Patel
    J. Blake Bartlett
    Jessica Vermeulen
    Thomas S. Lin
    Paul G. Richardson
    Peter Voorhees
    Blood Cancer Journal, 12
  • [8] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis
    Suzuki, Kazuhito
    Tsukada, Nobuhiro
    Nishimura, Noriko
    Nagata, Yasuyuki
    Okazuka, Kiyoshi
    Mishima, Yuko
    Yokoyama, Masahiro
    Nishiwaki, Kaichi
    Ishida, Tadao
    Yano, Shingo
    Terui, Yasuhito
    Suzuki, Kenshi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (01) : 103 - 111
  • [9] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: A multicenter retrospective comparative analysis
    Nishimura, Noriko
    Suzuki, Kazuhito
    Tsukada, Nobuhiro
    Nagata, Yasuyuki
    Okaduka, Kiyoshi
    Mishima, Yuko
    Yokoyama, Masahiro
    Nishiwaki, Kaichi
    Ishida, Tadao
    Yano, Shingo
    Terui, Yasuhito
    Suzuki, Kenshi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E214 - E215
  • [10] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin
    Voorhees, Peter M.
    Rodriguez, Cesar
    Reeves, Brandi
    Nathwani, Nitya
    Costa, Luciano J.
    Lutska, Yana
    Bobba, Padma
    Hoehn, Daniela
    Pei, Huiling
    Ukropec, Jon
    Qi, Ming
    Lin, Thomas S.
    Richardson, Paul G.
    BLOOD, 2020, 136
12345